Letters, Testimony & Comments

Dear Majority Leader Reid and Minority Leader McConnell: On behalf of the Biotechnology Industry Organization (BIO) and its more than 1...
March 16 2012
William D. Waddill, Senior Vice President and Chief Financial Officer OncoMed Pharmaceuticals highlights the importance of capital...
March 6 2012
On December 1, BIO submitted written testimony to the Senate Committee on Banking, Housing, and Urban Affairs on the importance of...
December 1 2011
Hearing Testimony Scott Koenig, M.D., PH.D. Before the House of Representatives Committee on Small Business Good morning Chairman...
April 7 2011
BIO advocated for the recently enacted new Therapeutic Discovery Project Credit program, which was created as a unique opportunity for...
August 3 2010
A letter to the House Ways & Means Committee by 54 trade organizations and companies supporting the extension of cellulosic biofuel...
June 23 2010
Access to Early Capital In the United States and globally, commercial development of biotechnology relies on the continuing...
May 27 2010
BIO and 34 companies and trade organizations sent a letter to Chairman Levin and Ranking Member Camp, of the House Ways and Means...
May 17 2010
Good morning Chairwoman Velázquez, Ranking Member Graves, Members of the Committee, the Staff of the Committee, ladies and...
October 14 2009
Good morning Chairman Wu, Ranking Member Smith, Members of the Committee, ladies and gentleman. I am Jim Greenwood, President and CEO of...
April 23 2009
BIO urges that changes to FIN46(R) accurately reflect the underlying economics of collaborations.
November 15 2008
The letter, signed by approximately 60 patient groups, emphasizes support for restoring eligibility in the SBIR program to venture-backed...
September 18 2008
BIO addresses concerns to FASB’s Staff Position on accounting for instrument C and conventional convertible debt.
October 27 2007
The letter, signed by over 280 biotech executives, emphasizes support for restoring eligibility in the SBIR program to venture-backed...
July 26 2005
To Hector Barreto, Administrator, U.S. Small Business Administration
November 4 2003
To Hector Barreto, Administrator, U.S. Small Business Administration
October 21 2003
Administrator, U.S. Small Business Administration
May 13 2003

Letters, Testimony & Comments

July 26 2012
Jeffrey S. Hatfield, President and Chief Executive Officer, Vitae Pharmaceuticals On behalf of the Biotechnology Industry...
March 16 2012
Dear Majority Leader Reid and Minority Leader McConnell: On behalf of the Biotechnology Industry Organization (BIO) and its more than 1...
March 6 2012
William D. Waddill, Senior Vice President and Chief Financial Officer OncoMed Pharmaceuticals highlights the importance of capital...
December 1 2011
On December 1, BIO submitted written testimony to the Senate Committee on Banking, Housing, and Urban Affairs on the importance of...
April 7 2011
Hearing Testimony Scott Koenig, M.D., PH.D. Before the House of Representatives Committee on Small Business Good morning Chairman...

Press Releases

June 6 2012
Washington, DC and New York, NY, Wednesday, June 6, 2012 -The 4th Annual Scientific American Worldview Report and...
April 5 2012
Washington, D.C. (April 5, 2012) – The Biotechnology Industry Organization expressed strong support for the...
March 22 2012
  Washington, DC (March 22, 2012) – The Biotechnology Industry Organization (BIO) applauds the Senate...
December 6 2011
Washington, DC (December 6, 2011) – The Biotechnology Industry Organization (BIO) announces program topics...
November 16 2011
Self-Funding Program Supported by Leading Biotech Trade Associations WASHINGTON, D.C. (November 16, 2011)...